Mirati Therapeutics has reported initial data from the Phase II KRYSTAL-7 clinical trial and KRYSTAL-1 Phase Ib cohort analysing a 400mg twice daily dose of adagrasib plus pembrolizumab to treat first-line non-small cell lung cancer (NSCLC) patients.

In both trials, the combination treatment was analysed as a first-line therapy in patients harbouring a KRASG12C mutation across all PD-L1 subgroups. 

At a median follow-up of 3.5 months, 75 participants were enrolled and could be analysed for safety. 

According to the latest findings, a concurrent combination regimen of adagrasib plus pembrolizumab showed tolerability and feasibility. 

Grade 1-2, Grade 3, and Grade 4 treatment-related adverse events were reported in the trial while no Grade 5 events were seen.

The combination therapy offered favourable initial clinical activity across all PD-L1 subgroups, with a 49% objective response rate (ORR) in evaluable subjects who received a minimum of one on-study scan.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

An ORR and disease control rate (DCR) of 57% and 100%, respectively, were seen in seven evaluable subjects in the KRYSTAL-1 Phase Ib cohort.

Safety in the KRYSTAL-1 Phase 1b cohort was also in line with those seen in KRSTYAL-7, with a manageable safety profile.

An investigational oral small-molecule KRASG12C inhibitor, adagrasib showed to have a durable half-life and widespread tissue distribution in studies.

Pembrolizumab is a PD-1/L1 checkpoint inhibitor.

Mirati Therapeutics research and development head, president and founder Chuck Baum said: “We look forward to progressing our clinical development in the first-line setting, with a goal of providing better options for patients with NSCLC harbouring a KRASG12C mutation. 

“This data further underscores the potential of adagrasib as a well-tolerated treatment option for patients. Based on these data, we look forward to initiating a Phase III trial.”

In January this year, the company reported positive results from the Phase II KRYSTAL-1 trial of a 600mg twice daily dose of adagrasib in pre-treated pancreatic ductal adenocarcinoma and other gastrointestinal tumour patients with a KRAS-G12C mutation.